The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Open accessAbstract
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in 2019 and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late phase in critically ill patients with SARS-CoV-2. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. Methods: The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2–infected Vero cells. Physiologically based pharmacokinetic (PBPK) models were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen while considering the drug’s safety profile. Results: Hydroxychloroquine (EC50 = 0.72 μM) was found to be more potent than chloroquine (EC50 = 5.47 μM) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached 3 times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance. Conclusions: Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationA novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · cited 1×
“The supernatant was collected, and, the RNA was extracted and analyzed by relative quantification using real-time reverse transcriptase–polymerase chain reaction (RT-PCR) (methods described in a previously published study) [13, 14].”
Self-citationWang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811
Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology
Schrezenmeier, E., & Dörner, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0372-x · Cited by 1,468
Effects of chloroquine on viral infections: an old drug against today's diseases
Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., & Cauda, R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00806-5 · Cited by 1,268
[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].
Chen, L., Liu, H., Liu, W. Y., Liu, J., Liu, K., Shang, J., Deng, Y., & Wei, S. (2020) · PubMed · doi:10.3760/cma.j.issn.1001-0939.2020.0005 · Cited by 693
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Ranst, M. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 649
On the use of corticosteroids for 2019-nCoV pneumonia
Shang, L., Zhao, J., Hu, Y., Du, R., & Cao, B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30361-5 · Cited by 604
Mechanism of action of hydroxychloroquine as an antirheumatic drug
Fox, R. I. (1993) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(10)80012-5 · Cited by 430
Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral Activities
Biot, C., Daher, W., Chavain, N., Fandeur, T., Khalife, J., Dive, D., & De Clercq, E. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0601856 · Cited by 320
Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate
McChesney, E. W. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)91265-2 · Cited by 310
Bioavailability of hydroxychloroquine tablets in healthy volunteers.
Tett, S., Cutler, D., Day, R., & Brown, K. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03439.x · Cited by 269
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases
Furst, D. E. (1996) · Lupus · doi:10.1177/0961203396005001041 · Cited by 233
Strand, V., Ahadieh, S., French, J., Geier, J., Krishnaswami, S., Menon, S., Checchio, T., Tensfeldt, T. G., Hoffman, E., Riese, R., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0880-2 · Cited by 223
Tett, S., Cutler, D., Day, R., & Brown, K. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb05281.x · Cited by 177
Li, C., Zhu, X., Ji, X., Quanquin, N., Deng, Y.-Q., Tian, M., Aliyari, R., Zuo, X., Yuan, L., Afridi, S. K., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.09.034 · Cited by 169
In vitro inhibition of human influenza A virus replication by chloroquine.
Ooi, E. E., Chew, J. S. W., Loh, J. P., & Chua, R. (2006) · Virology Journal · doi:10.1186/1743-422x-3-39 · Cited by 140
Chloroquine and Hydroxychloroquine as Inhibitors of Human Immunodeficiency Virus (HIV-1) Activity
Romanelli, F., Smith, K. M., & Hoven, A. D. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383791 · Cited by 102
Abdel‐Aziz, A. K., Shouman, S. A., El‐Demerdash, E., Elgendy, M., & Abdel‐Naim, A. B. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.04.007 · Cited by 95
Collins, K. P., Jackson, K. M., & Gustafson, D. L. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.245639 · Cited by 83
Endocytosis and chloroquine accumulation during the cell cycle of hepatoma cells in culture.
QUINTART, J., Leroy‐Houyet, M., Trouet, A., et al. (1979) · The Journal of Cell Biology · doi:10.1083/jcb.82.3.644 · Cited by 59
Literature-based review of the drugs used for the treatment of COVID-19
Venkatasubbaiah, M., Reddy, P. D., & Satyanarayana, S. V. (2020) · Current Medicine Research and Practice · doi:10.1016/j.cmrp.2020.05.013 · Cited by 51
Fan, H., Ma, Z., Chen, J., Yang, X., Cheng, J., & Li, Y. (2015) · Rheumatology and Therapy · doi:10.1007/s40744-015-0012-0 · Cited by 40
Prevention of Chloroquine Absorption by Activated Charcoal
Neuvonen, P. J., Kivistö, K. T., Laine, K., & Pyykkö, K. A. (1992) · Human & Experimental Toxicology · doi:10.1177/096032719201100210 · Cited by 35
Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?
Giammaria, D., & Pajewski, A. (2020) · Journal of Global Health · doi:10.7189/jogh.10.010377 · Cited by 26
Hsueh, C., Hsu, V., Pan, Y., & Zhao, P. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0635-8 · Cited by 19
A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance
Ahn, B. Y., Kang, C. K., Seo, J. D., Choe, P. G., Song, S. H., Park, W. B., Park, S., Kim, N. J., & Oh, M. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e231 · Cited by 9
Cited by
Characteristics of SARS-CoV-2 and COVID-19
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedThe trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
Prem, K., Liu, Y., Russell, T. W., Kucharski, A. J., Eggo, R. M., Davies, N., Flasche, S., Clifford, S., Pearson, C. A. B., Munday, J. D., et al. (2020) · The Lancet Public Health · doi:10.1016/s2468-2667(20)30073-6 · Cited by 2,114
Metadata
- Authors
- Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., Zhan, S., Lu, R., Li, H., Tan, W., & Liu, D.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03-09
- Volume
- 71
- Issue
- 15
- Pages
- 732-739
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3009577418
- Cited by
- 2,662
- References
- 28
- FWCI
- 76.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.